Sequent Scientific Valuation

Q: What is the Fair Price of 512529 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

512529 (₹123.55) is trading above our estimate of [[fair value]] (₹28.23)

Is 512529 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 512529 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 512529 (₹123.55) is trading above our estimate of fair value (₹28.23)

Significantly Below Fair Value: 512529 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 512529?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for 512529. This is calculated by dividing 512529's market cap by their current preferred multiple.
What is 512529's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	₹30.70b

512529 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	2.6x
Enterprise Value/EBITDA	99.2x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 512529's PS Ratio compare to its peers?

The above table shows the PS ratio for 512529 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	4.7x
SUPRIYA Supriya Lifescience	5.8x	19.5%	₹31.9b
JSLL Jeena Sikho Lifecare	9.2x	n/a	₹25.3b
524735 Hikal	2.1x	13.3%	₹37.4b
INDOCO Indoco Remedies	1.7x	10.3%	₹30.1b
512529 Sequent Scientific	2.2x	n/a	₹30.7b

Price-To-Sales vs Peers: 512529 is good value based on its Price-To-Sales Ratio (2.2x) compared to the peer average (4.7x).

Price to Earnings Ratio vs Industry

How does 512529's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	18.8%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	18.8%
	n/a	n/a	n/a

No more companies

Price-To-Sales vs Industry: 512529 is good value based on its Price-To-Sales Ratio (2.2x) compared to the Indian Pharmaceuticals industry average (2.7x).

Price to Sales Ratio vs Fair Ratio

What is 512529's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

512529 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	2.2x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 512529's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.